CD38 and AL amyloidosis: If it was not used first-line, it ishighly effective in relapse and can be given either alone or with other agents(trials show daratumumab monotherapy yields ≈40% responses in AL).Another anti-CD38 antibody, isatuximab, is in clinical trials for refractory ALamyloidosis​.